See today's BioWorld
To read the full story, subscribe or sign in.

Cabaletta acquires global rights to CD19 binder from Iaso Bio in $162M deal

Oct. 13, 2022
By Doris Yu
Nanjing Iaso Biotherapeutics Co. Ltd. has out-licensed a fully human anti-CD19 binder to Cabaletta Bio Inc. in a deal worth up to $162 million.
BioWorld Deals and M&A Immune China